Sponsor introductory remarks on measure. (CR H122)
The bill mandates Medicare and Medicaid coverage of peripheral artery disease (PAD) screening tests for defined at-risk populations without cost-sharing, requires the HHS Secretary to set screening frequency standards, and prohibits eliminating that preventive benefit. It creates a CDC PAD education program with $6 million annually (2026–2030), requires development and incorporation of quality measures to reduce nontraumatic lower-limb major amputations into Medicare reporting and payment programs, and directs CMMI to test an amputation prevention model within 18 months.
Cost and federal spending versus long-term savings emphasis
Relative to its intended legislative type, this bill is a clearly articulated substantive change to Medicare and Medicaid coverage and payment rules for peripheral artery disease screening, coupled with programmatic additions (CDC education), quality-measure development, and a CMMI pilot.
The bill mandates Medicare and Medicaid coverage of peripheral artery disease (PAD) screening tests for defined at-risk populations without cost-sharing, requires the HHS Secretary to set screening frequency standards, and prohibits eliminating that preventive benefit.
It creates a CDC PAD education program with $6 million annually (2026–2030), requires development and incorporation of quality measures to reduce nontraumatic lower-limb major amputations into Medicare reporting and payment programs, and directs CMMI to test an amputation prevention model within 18 months.
Many definitional and implementation details (tests, at-risk criteria, frequency) are specified, with most coverage changes effective January 1, 2026.
Content is bipartisan‑friendly and technical, but budgetary impact, Medicaid federalism issues, and Senate hurdles reduce near-term chances.
Relative to its intended legislative type, this bill is a clearly articulated substantive change to Medicare and Medicaid coverage and payment rules for peripheral artery disease screening, coupled with programmatic additions (CDC education), quality-measure development, and a CMMI pilot. The statutory drafting integrates directly with the Social Security Act and specifies roles and timelines for implementation.
Cost and federal spending versus long-term savings emphasis
These are examples from the analysis, not a ranked list of the most-affected groups.
Cost and federal spending versus long-term savings emphasis
Likely strongly supportive.
The bill expands preventive care, removes financial barriers, and targets disparities in amputation rates among minorities.
It couples coverage with education, quality measures, and a CMMI model to drive systemic improvement.
Generally favorable but pragmatic and cautious.
Supports preventive coverage and quality measures, while seeking clear frequency standards, cost estimates, and guardrails against overuse.
Wants measurable budget and implementation plans.
Skeptical.
Supports reducing amputations but concerned about new mandated coverage, federal spending, and expanded CMS authority.
Worries about overuse, unfunded mandates on states, and increased bureaucracy.
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Still ahead
Content is bipartisan‑friendly and technical, but budgetary impact, Medicaid federalism issues, and Senate hurdles reduce near-term chances.
The bill has not accumulated any surfaced votes yet.
Cost and federal spending versus long-term savings emphasis
Content is bipartisan‑friendly and technical, but budgetary impact, Medicaid federalism issues, and Senate hurdles reduce near-term chances.
Relative to its intended legislative type, this bill is a clearly articulated substantive change to Medicare and Medicaid coverage and payment rules for peripheral artery disease screening, coupled with programmatic add…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.